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Key Points: 
1. Compared to placebo, hydroxyurea did not increase the incidence or severity of malaria
events in Ugandan children with sickle cell anemia
2. Hydroxyurea provided significant clinical and laboratory benefits, suggesting it will be safe
and effective across sub-Saharan Africa
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ABSTRACT 
Hydroxyurea treatment is recommended for children with sickle cell anemia (SCA) living in high-
resource malaria-free regions, but its safety and efficacy in malaria-endemic sub-Saharan Africa, 
where the greatest sickle cell burden exists, remain unknown.  In vitro studies suggest 
hydroxyurea could increase malaria severity, and hydroxyurea-associated neutropenia could 
worsen infections.  NOHARM was a randomized, double-blinded, placebo-controlled trial 
conducted in malaria-endemic Uganda, comparing hydroxyurea to placebo at 20  2.5 
mg/kg/day for 12 months.  The primary outcome was incidence of clinical malaria.  Secondary 
outcomes included SCA-related adverse events, clinical and laboratory effects, and 
hematological toxicities.  Children received either hydroxyurea (N=104) or placebo (N=103).  
Malaria incidence did not differ between children on hydroxyurea [0.05 episodes/child/year, 
95% CI (0.02, 0.13)] versus placebo [0.07 episodes/child/year (0.03, 0.16)]; the 
hydroxyurea/placebo malaria incidence rate ratio was 0.7 [(0.2, 2.7), p=0.61].  Time to infection 
also did not differ significantly between treatment arms.  A composite SCA-related clinical 
outcome (vaso-occlusive painful crisis, dactylitis, acute chest syndrome, splenic sequestration, 
or blood transfusion) was less frequent with hydroxyurea (45%) than placebo (69%, p=0.001).  
Children receiving hydroxyurea had significantly increased hemoglobin concentration and fetal 
hemoglobin, with decreased leukocytes and reticulocytes.  Serious adverse events, sepsis 
episodes, and dose-limiting toxicities were similar between treatment arms.  Three deaths 
occurred (two hydroxyurea, one placebo, none from malaria).  Hydroxyurea treatment appears 
safe for children with SCA living in malaria-endemic sub-Saharan Africa, without increased 
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severe malaria, infections, or adverse events.  Hydroxyurea provides SCA-related laboratory 
and clinical efficacy, but optimal dosing and monitoring regimens for Africa remain undefined. 
INTRODUCTION 
Sickle cell anemia (SCA) is a life-threatening hematological disorder and among the 
world’s most prevalent hereditary diseases, with over 300,000 affected babies born each year.1 
The vast majority of these births occur in sub-Saharan Africa, where an estimated 50-90% of 
children with SCA will die by age five years, often without an established diagnosis.2  The 
heterozygous sickle gene mutation confers a strong survival advantage against malaria,3 which 
explains why the allele frequency is highest in malaria-endemic regions of Africa.1   
Hydroxyurea has proven laboratory and clinical efficacy for both children and adults 
with SCA.4-7  Its mechanisms of action are multiple and incompletely understood, but fetal 
hemoglobin (HbF) induction in erythroid cells is critical for the inhibition of intracellular sickling. 
Treatment also has salutary effects on blood cell adhesion, morphology, and rheology.8  
Further, hydroxyurea is a safe drug for SCA, with low incidence of treatment-related toxicity 
and no serious long-term effects observed to date.  Hydroxyurea is currently approved by the 
US Food and Drug Administration for adults with severe symptoms and by the European 
Medicines Agency for affected adults and children above age two years.  Based on a large and 
compelling body of evidence accumulated over the past 30 years, evidence-based guidelines 
published by the National Heart, Lung and Blood Institute of the National Institutes of Health 
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strongly recommend wider usage, including offering treatment to infants as young as nine 
months of age.9 
The benefits of hydroxyurea treatment for children with SCA would be greatest in 
countries within sub-Saharan Africa, if hydroxyurea were found to be safe and have its 
predicted efficacy in these high-burden areas.  However, the effects of hydroxyurea on the 
presentation and clinical course of malaria must also be considered.  Hydroxyurea may directly 
affect several factors related to the pathogenesis of severe malaria, with potentially deleterious 
consequences.  Some in vitro and animal studies suggest that hydroxyurea increases 
endothelial intracellular adhesion molecule-1 (ICAM-1) expression,10 which could enhance 
parasite adhesion to endothelium,11 and also increases TNF- levels,12 both of which are 
associated with increased malaria severity and death.13  Other studies have challenged these 
findings,14,15 but definitive human data are lacking.  If hydroxyurea induces effects that shift the 
clinical course in SCA from uncomplicated to severe malaria, this could increase mortality 
despite benefits for the underlying SCA.16  In addition, in low-resource settings, hydroxyurea 
may cause neutropenia that could lead to increased severity of the many bacterial infections 
commonly observed in African children with SCA.17   
In contrast to these adverse effects, it is possible that hydroxyurea could have beneficial 
effects against malaria since HbF, which is increased by hydroxyurea, inhibits Plasmodium 
falciparum growth in vitro.18  Hydroxyurea treatment also generates nitric oxide,19 which 
protects against severe malaria in animals20,21 and humans.22  With these contrasting potential 
mechanisms, the risks and benefits of hydroxyurea in a malaria endemic setting remain 
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unknown, and many critical questions remain regarding the safety, feasibility, and efficacy of 
hydroxyurea for children with SCA living in malaria-endemic settings within sub-Saharan Africa. 
For these reasons, we conducted a prospective randomized controlled double-blinded 
placebo-controlled clinical trial, the Novel use Of Hydroxyurea in an African Region with Malaria 
(NOHARM), in young Ugandan children with SCA, to determine the safety and efficacy of 
hydroxyurea in a malaria-endemic region. NOHARM is registered on ClinicalTrials.gov as 
NCT01976416. 
METHODS 
Study design.  A detailed description of the study site, design, and procedures was previously 
published.23  Briefly, NOHARM was a randomized double-blinded placebo-controlled clinical 
trial.  Due to concerns about the risks of severe malaria and infection with hydroxyurea 
treatment, the consensus among local experts and the local institutional review board 
supported a placebo-controlled trial, despite the expected SCA-related treatment benefits in 
children with SCA.  It was agreed, however, that study participants should be given the 
opportunity to receive subsequent open-label hydroxyurea, if no danger signal was observed 
from the blinded study treatment.  NOHARM was conducted at Mulago Hospital Sickle Cell 
Clinic (MHSCC) in Kampala, Uganda.  Kampala has seasonal malaria transmission, with high 
outpatient and inpatient burdens.  Protocol approval was obtained from the institutional 
review boards of the Makerere University School of Medicine, Indiana University, University 
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of Minnesota, and Cincinnati Children’s Hospital, as well as the Uganda National Drug 
Authority and Uganda National Council for Science and Technology.   
Study participants.  Children receiving care at MHSCC were eligible if 1.00-3.99 years of age 
and living within 50km of the clinic.  Study inclusion criteria included confirmed SCA, weight 
≥5.0kg, and willingness to comply with study procedures.  Children with severe malnutrition 
or known chronic medical conditions, current hydroxyurea treatment, or blood transfusion in 
the previous 30 days were excluded.  Parents of the study participants gave written informed 
consent. 
Randomization and masking.  Children meeting inclusion criteria completed enrolment and 
after screening, were randomized 1:1 to hydroxyurea or placebo by the Data Coordinating 
Center (DCC) at Cincinnati Children’s Hospital as described.23  Study allocations were 
randomly assigned by the statistician, using computer-generated sequences in block files of 8 
participants.  Study treatments were supplied with A or B labels, and the clinical coordinating 
center staff, study pharmacists, families and caregivers, and all but two members of the DCC 
were masked to treatment allocation. 
Medications.  Study treatment (Addmedica, Paris) included oral hydroxyurea (Siklos®) as 
1000mg scored tablets and 100mg dispersible tablets, or placebo tablets of identical size and 
appearance.  Treatment was administered once daily at 20 ± 2.5 mg/kg for 12 months, with 
dose adjustments in both arms for weight gain and hematological toxicities.23  
Procedures.  All participants received standard care for SCA including folic acid, penicillin 
prophylaxis, and pneumococcal vaccination.  For malaria prophylaxis, children received 
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insecticide-treated mosquito nets and monthly sulphadoxine-pyrimethamine.  Study 
participants were seen for the randomization visit (Month 0), and for scheduled visits at 2 
weeks post treatment initiation, monthly from months 1-4, and at months 6, 8, 10 and 12 for 
a total of ten scheduled visits with monitoring for clinical malaria and toxicities.  Caregivers 
were instructed to return to clinic or hospital whenever the child was unwell; all febrile 
children received malaria testing.  After completing the blinded treatment phase, participants 
could receive open-label hydroxyurea, as per local Ethics Committee recommendations. 
Measurements.  Complete blood counts with leukocyte differential and absolute reticulocyte 
count (ARC) were measured at each visit (Sysmex Corporation, Kobe, Japan) plus blood 
chemistries using a Cobas 6000 analyzer Model C501 (Roche Diagnostics, Indianapolis, USA).  
HbF was quantified by capillary electrophoresis (Minicap, Sebia, Paris France).  Malaria was 
assessed by peripheral blood smear using Giemsa staining: each slide was read by two 
certified microscopists, with a third reading to resolve any discrepancies. 
Clinical definitions.  All children with measured fever (axillary temperature ≥37.5C) in the 
clinic or fever by history were tested for malaria by microscopy.  Children with measured 
fever or a history of fever and detectable Plasmodium species infection of any density on 
blood smear were diagnosed with clinical malaria, as is standard in this area.  Malaria was 
treated with parenteral artesunate followed by oral artemether-lumefantrine, if the child was 
hospitalized, or oral artemether-lumefantrine, if the child was not hospitalized.  The diagnosis 
of sickle-related clinical events followed published definitions,24 with modifications such as 
pneumonia based on clinical rather than X-ray findings.  Clinical sepsis was defined as 
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presentation with fever and an unwell appearance, for which intravenous antibiotics were 
given.  Full definitions for clinical adverse events are provided in Table 1. 
Study outcomes.  The primary study outcome was incidence of clinical malaria.  Secondary 
outcomes included: (1) a composite of one or more SCA-related adverse events (pain, 
dactylitis, acute chest syndrome, splenic sequestration, or transfusion); (2) clinical adverse 
events; and (3) dose-limiting toxicities. 
Statistical analysis.  We estimated malaria incidence would be between 0.3 and 1.3 malaria 
episodes per year, based on a study based in Kampala that includes community children 
(lowest incidence estimate) and children with severe malaria (highest incidence estimate) (CC 
John, unpublished data).  With these rates of malaria incidence, and variance to mean ratio 
1.7, we estimated that 100 children per treatment arm would provide 90% power (alpha = 
0.05) to detect between 59% and 34% difference in incidence between treatment arms, 
respectively.  Study data were entered into OnCore and analyzed using R (Vienna, Austria, 
version 3.2.4).  The primary analysis included all randomized participants per intention-to-
treat, with p<0.05 considered significant.  Interim analysis for safety was performed after 100 
children completed blinded study treatment.  The difference in malaria incidence rate 
between the hydroxyurea and placebo groups was analyzed using negative binomial 
regression.  For secondary outcomes, p<0.01 was considered significant.  Continuous 
measures are described as Mean (SD), and treatment arms were compared using the two-
sample Welch’s t-test, or when within the same individuals using a paired Welch’s t-test.  
Categorical measures are described using percent or frequency, and compared using the 
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Pearson χ2 test with Yates correction or Fisher’s exact test.  Malaria episodes are reported as 
mean per child (95% CI).  Time to malaria infection is described by Kaplan-Meier curves.  
Groups were compared for cumulative incidence (i.e., time to infection) using Gray’s method, 
with all-cause death treated as a competing event.25 
RESULTS 
A total of 213 children were enrolled between September 24, 2014 and October 2, 
2015; among these, 208 were randomized to either hydroxyurea or placebo (Figure 1).  One 
child was later deemed ineligible due to an elevated baseline ALT, so that child’s data were 
removed from the analyzed dataset.  The treatment arms had similar baseline demographic, 
laboratory, and clinical measures (Table 2).  No child had symptomatic or asymptomatic 
Plasmodium species parasitemia at enrollment. 
Malaria occurred at a low rate throughout the study, perhaps reflecting excellent 
adherence to malaria prophylaxis.  Over the one year study period, malaria testing was done for 
235 episodes of measured fever or history of fever in study participants, with only 12 fever 
episodes due to malaria.  Malaria incidence did not differ between children prescribed 
hydroxyurea [0.05 episodes per child per year, 95% CI (0.02, 0.13)] versus placebo [0.07 
episodes per child per year (0.03, 0.16)]; the hydroxyurea/placebo malaria incidence rate ratio 
was 0.7 [(0.2, 2.7), p=0.61].  Time to infection also did not differ significantly between 
hydroxyurea and placebo (Figure 2).  All 12 malaria episodes were due to P. falciparum; one 
child had co-infection with P. malariae.  Three children on hydroxyurea had a total of five 
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malaria episodes, compared to seven children on placebo with a total of seven malaria episodes 
(Table 3).  The median parasite density was 26,410 parasites/µL (minimum, 1,064; maximum, 
193,705).  Six of the 12 episodes of malaria were severe, requiring hospitalization (two with 
hemoglobin concentration <5 g/dL, one with impaired consciousness, one with hemoglobin 
concentration <5 g/dL and impaired consciousness, and two unable to take oral medication).  
All ten study participants with malaria recovered.  In the 12 confirmed cases of malaria, there 
were 4 episodes with concomitant clinical AE:  Vaso-occlusive pain crisis (N=3) and 
ACS/pneumonia (N = 1).  In addition, there were 2 episodes of malaria with concomitant SAE: 
splenic sequestration (N=1) and bacteremia (N=1). 
A per-protocol composite clinical outcome included one or more SCA-related clinical 
events (vaso-occlusive painful crisis, dactylitis, acute chest syndrome/pneumonia, splenic 
sequestration, or blood transfusion).  The proportion of children with this outcome was 
significantly lower in the hydroxyurea arm than the placebo arm (45% versus 69%, Table 3, 
p=0.001).  For individual clinical events, vaso-occlusive pain and hospitalizations were 
significantly less frequent with hydroxyurea than placebo (Table 3, Figure 3).  This difference in 
hospitalization rate was largely driven by differences in vaso-occlusive crises, which accounted 
for 42% of all hospitalizations.  The number needed to treat to prevent one hospitalization was 
6.4, while the number needed to treat to prevent a SCA-related event was 2.5.  No strokes 
occurred in either treatment arm during the one-year treatment period.  Clinical sepsis was 
more frequent with placebo (12.6%) than hydroxyurea (5.8%), but this difference was not 
statistically significant (p=0.14).  Blood cultures were positive in only two episodes, both for 
Staphylococcus aureus, one in each treatment arm. 
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Serious adverse events, defined as death, an acute life-threatening event, or 
hospitalization for more than seven days, occurred equally with six in each treatment arm 
(Table 3).  During the blinded treatment phase, three children died (two hydroxyurea, one 
placebo) and five others withdrew from the study.  Causes of death were presumed sepsis (one 
hydroxyurea, one placebo) and sudden death, cause unknown (hydroxyurea).  In two of the SAE 
listed in Table 3, two participants had malaria concomitant with bacteremia or splenic 
sequestration, as noted above. 
The two treatment arms had similar counts of laboratory adverse events except anemia 
(Table 3).  Specifically, low hemoglobin (<6.0 g/dL) occurred more frequently in children 
receiving placebo than hydroxyurea, while the frequencies of neutropenia, thrombocytopenia 
and reticulocytopenia did not differ significantly between treatment arms.  Similarly, the 
frequency of protocol-defined dose-limiting hematological toxicities did not differ between 
treatment arms (Table 3).  Neutropenia was notably rare, occurring only once in only two 
participants over the entire study. 
Children receiving hydroxyurea had significant treatment-associated increases in 
hemoglobin concentration, mean corpuscular volume (MCV), and HbF compared to those 
receiving placebo (Table 4).  Substantial increases in HbF were observed for both children 
below and above the median enrollment age, despite starting with different baseline HbF 
levels.  Conversely, children on hydroxyurea had significant decreases in white blood cell count, 
absolute neutrophil count, absolute reticulocyte count, and platelets compared to children 
receiving placebo (Table 4).  The treatment arms did not differ in changes in alanine transferase 
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or creatinine.  Medication adherence, assessed by careful questioning at each clinic visit, was 
deemed excellent in both treatment arms. 
DISCUSSION 
In this prospective randomized double-blinded placebo-controlled trial of young 
children with SCA living in Uganda, hydroxyurea therapy was both safe and efficacious.  The two 
treatment arms did not differ in the incidence, severity, or other outcomes from malaria 
infection; in the incidence of clinical sepsis or bacteremia; or in the number of laboratory 
adverse events or dose-limiting toxicities, including neutropenia.  In contrast, the previously 
described laboratory and clinical benefits of hydroxyurea therapy were clearly observed in this 
young population.  The increases in hemoglobin concentration and HbF levels, along with 
decreases in neutrophils and reticulocytes, were similar to values observed in US-based trials,4-
7,26 while the rates of important clinical SCA-related events such as vaso-occlusive painful crisis 
and hospitalizations were similarly reduced.  Taken together, these data suggest that 
hydroxyurea should be strongly considered as an important therapeutic option for young 
children with SCA living in malaria endemic areas. 
NOHARM represents the first randomized trial of hydroxyurea in Africa. The study 
design captured all possible malaria events, with blood smear testing for all episodes of current 
and recent fever.  The incidence of malaria in our cohort was low, suggesting effective 
protection by insecticide-treated bed nets and monthly oral malaria prophylaxis with 
sulfadoxine-pyrimethamine provided to all study participants, or possibly a decreased risk of 
14 
clinical malaria in children with SCA.  Some form of malaria prophylaxis for children with SCA is 
a standard recommendation in most African countries,27 and insecticide-treated bed net use for 
children <5 years of age in malaria endemic areas of Africa has increased dramatically over the 
past decade, to an average of >60% coverage,28 so the preventive measures used in this study 
are similar to those in many other malaria endemic areas where children with SCA live.  
However, adherence to these recommendations is highly variable, so our study findings may 
not apply to children with SCA not on malaria prophylaxis and/or not using insecticide-treated 
bed nets.  Since malaria incidence was low in our study, the range of relative differences in 
malaria incidence between hydroxyurea and placebo is broad (95% CI for incidence rate ratio 
0.2 to 2.7), but the absolute differences in episodes is small (95% CI 2-13 episodes/100 
children/year with hydroxyurea versus 3-16 episodes/100 children/year with placebo).  
Hydroxyurea did not worsen malaria severity, since hospitalizations for malaria did not differ 
between treatment arms, and no child died of malaria.  Because of the low malaria incidence, 
this study does not provide definitive guidance regarding the safety of hydroxyurea in all 
malaria endemic areas, but the lack of increased risks of malaria incidence, severity, and 
outcome is reassuring.  The incidence of malaria in these children with SCA further suggests 
that absolute differences in malaria risk with hydroxyurea will be very small.  However, risks of 
hydroxyurea may differ in areas of higher malaria transmission, and genetic or environmental 
factors in other areas could affect risk of hydroxyurea toxicity or malaria-hydroxyurea 
interactions. In light of the present study data showing efficacy of hydroxyurea against pain 
crises and hospitalizations, with no evidence of increased malaria or infection risk in this area of 
low malaria transmission, it may be difficult to justify additional placebo-controlled trials in 
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areas of higher malaria transmission. If additional placebo-controlled studies are not 
conducted, future studies of open-label hydroxyurea in other malaria endemic regions should 
carefully document the rates and complications of malaria during hydroxyurea treatment.  
These data will help determine the long-term safety profile of hydroxyurea for children living in 
malaria-endemic regions. 
All five of the study children hospitalized with severe malaria (one child was hospitalized 
twice) survived, in contrast to an earlier study from Kenya in which four of five children with 
SCA hospitalized for severe malaria died (80% mortality).16  The presence of malaria parasites 
on peripheral blood smear also did not increase the risk of death during hospitalization, 
contrasting with a Tanzanian study of children with SCA, which reported increased mortality in 
hospitalized children with parasitemia.29  In contrast, another study from Kenya reported no 
deaths among 38 children with SCA and severe malarial anemia, the most common form of 
severe malaria affecting these children.30  Similarly, in a recent study in Kampala conducted by 
our group, none of 22 children with SCA who developed severe malarial anemia died.31 
Together, these study findings cast doubt on the contention that severe malaria causes high 
rates of mortality in children with SCA.  In the first two studies cited, which described increased 
mortality from malaria in children with SCA, malaria prophylaxis was either not given 
routinely16 or consisted of chloroquine.29  The sulfadoxine-pyrimethamine prophylaxis given in 
the present study is likely more effective than chloroquine prophylaxis.  In addition, the two 
studies were conducted during a period of much lower bed net coverage, and a significant 
proportion of children in these earlier study cohorts received chloroquine or sulfadoxine-
pyrimethamine for treatment of uncomplicated malaria, instead of the more effective current 
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standard of care, artemisinin-combination therapy.  Together, these factors may have played a 
role in the higher mortality seen with malaria in these prior cohorts. 
Increased infection in children with drug-induced neutropenia was an additional 
concern regarding hydroxyurea treatment in an area where invasive bacterial infection is 
common in children.  However, neutropenia was rare in NOHARM and did not differ on 
hydroxyurea versus placebo treatment, and episodes of pneumonia, clinically defined sepsis, 
and bacteremia did not differ between hydroxyurea or placebo treatment arms.  These data 
confirm findings observed in the US,5 and should help allay safety concerns about hydroxyurea 
and infection risk related to neutropenia in low-resource settings. 
Hydroxyurea was also associated with significantly fewer SCA-related clinical events, 
specifically vaso-occlusive crises, dactylitis, and hospitalizations. Other laboratory outcomes of 
long-term clinical importance for children with SCA, including increases in hemoglobin 
concentration and HbF, as well as decreases in leukocyte, neutrophil, and reticulocyte counts, 
were all more favorable in children receiving hydroxyurea than placebo, further supporting the 
drug's efficacy in this study population.  Despite the differences in nutritional status from US-
based populations, as evidenced by the low baseline Z-scores, the hydroxyurea responses were 
remarkably similar to published results in the BABY HUG trial for both clinical and laboratory 
effects.5  The potential benefits of hydroxyurea treatment on growth in NOHARM are also 
important to assess, but have not yet undergone formal analysis.  
After the double-blinded treatment phase, the entire NOHARM cohort was offered 
open-label hydroxyurea as per the study design, and all but one family opted for treatment. 
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Future analysis can thus compare the effects of early initiation and the longer-term effects of 
treatment. Since hydroxyurea escalated to maximum tolerated dose is standard in the US,7,25 
additional studies should assess how SCA-related adverse events and hematological responses 
compare for children receiving fixed-dose treatment versus dose escalation regimens.  
Outcomes were excellent in the present study with a safe and relatively easily administered 
fixed dose (20 mg/kg), so it will be important to investigate how treatment benefits and risks 
differ with different dosing schemes of hydroxyurea for children with SCA living in malaria-
endemic areas.  Children in African countries often have limited access to health care facilities 
and those facilities typically have limited lab testing capability.  Less frequent laboratory 
monitoring would allow wider implementation of hydroxyurea treatment. 
Additional studies that include longer duration of hydroxyurea in malaria-endemic areas 
will help determine optimal drug dosing, the range of adverse events, and malaria incidence in 
areas with higher malaria transmission.  Until then, the present study documents that with 
adequate monitoring, mosquito nets, and malaria prophylaxis, fixed-dose hydroxyurea 
treatment for children with SCA in malaria-endemic areas is safe with no increased incidence of 
malaria, sepsis, bacteremia, or serious adverse events.  In combination with the observed 
clinical efficacy (fewer painful events and hospitalizations), the NOHARM study findings support 
the wider use of hydroxyurea for children with SCA living in malaria-endemic regions across 
sub-Saharan Africa. 
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Table 1. NOHARM Adverse Event Definitions.* 
Clinical Adverse Event Terminology Definition 
 Vaso-Occlusive Pain Crisis/Dactylitis 
Vaso-occlusive pain crisis: acute pain and 
tenderness in an area of the body, with or 
without swelling, with no other diagnostic 
explanation.  
Dactylitis: Vaso-occlusive crisis (acute pain, 
tenderness, and swelling) localized to hands or 
feet. 
 Pneumonia/Acute Chest Syndrome 
Pneumonia: history of fever or measured axillary 
temperature ≥37.5˚C, with tachypnea and cough.  
Acute chest syndrome: signs of pneumonia above 
plus chest pain and/or tenderness. 
 Clinical Sepsis 
Measured fever and ill appearance, requiring IV 
antibiotics 
 Acute Splenic Sequestration 
Increase in splenic size from last physical 
examination, accompanied by a decrease in 
hemoglobin of ≥2 g/dL 
 Upper Respiratory Infection 
Child with general well appearance with 
rhinorrhea, nasal congestion or cough 
 Gastrointestinal-related 
Diarrhea, vomiting, constipated, intestinal 
obstruction 
 Malaria 
Measured fever (axillary temperature ≥37.5ºC) or 
fever by history and Plasmodium species infection 
on blood smear  
 Other infection Other infections, diagnosed clinically 
 Other (e.g., injury) 
Other diseases not included above diagnosed 
during visits for illness 
Laboratory Adverse Events** Definition 
 Anemia Hemoglobin < 6 g/dL 
 Reticulocytopenia 
Absolute reticulocyte count <80 x 109/L and 
hemoglobin < 7 g/dL 
 Neutropenia Absolute neutrophil count <1.0 x 109/L 
 Thrombocytopenia Platelet count <80 x 109/L 
 Elevated AST/ALT AST>150 IU/L, ALT>150 IU/L 
 Elevated Bilirubin Total bilirubin > 5 mg/dL 
* The diagnosis of sickle-related clinical events followed published definitions,24 with
modifications such as pneumonia and clinical sepsis.
**Laboratory AE definitions represent the values necessary for a Grade 2 event.
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Table 2.  Baseline demographic, clinical, and laboratory characteristics of the NOHARM 
randomized cohort.  
Hydroxyurea 
(N=104) 
Placebo 
(N=103) 
P-Value
Demographics, N (%) 
 Age at enrollment (years), mean (SD) 2.2 (0.9) 2.3 (0.9) 0.3148 
 Male 55 (53%) 57 (55%) 0.8298 
 Parent completing secondary school 32 (31%) 35 (34%) 0.7614 
 Running water in the home 14 (13%) 11 (11%) 0.6885 
Growth Measures, Mean (SD) 
 Height (cm) 85.6 (8.8) 86.3 (8.2) 0.5615 
 Weight (kg) 11.3 (2.1) 11.5 (2.1) 0.4604 
Z-score (weight for length/height) -0.40 (1.06) -0.39 (1.06) 0.9316 
Past Medical History, N (%) 
 Dactylitis 80 (77%) 82 (80%) 0.7639 
 Vaso-Occlusive Crisis 88/103 (85%) 81/103 (79%) 0.3421 
 Stroke 0 0 - 
 Splenomegaly 6/93 (6%) 5/99 (5%) 0.7619^ 
 Acute chest syndrome 21/103 (20%) 13/100 (13%) 0.2219 
 Transfusion 56 (54%) 57 (55%) 0.9393 
 Hospitalization within 1 year of enrollment 65 (63%) 54 (52%) 0.1851 
Laboratory Measures, Mean (SD) 
 Hemoglobin (g/dL) 7.5 (1.1) 7.6 (1.0) 0.5214 
 Mean corpuscular volume (MCV, fL) 79 (9) 80 (9) 0.8248 
 Fetal hemoglobin [(HbF)/(HbF + HbS), %)] 14.6 (7.1) 13.3 (6.0) 0.1591 
 Absolute reticulocyte count (ARC, x 109/L) 380 (122) 381 (112) 0.9623 
 White blood cell count (WBC, x 109/L) 19.0 (7.2) 18.7 (5.4) 0.7148 
 Absolute neutrophil count (ANC, x 109/L) 6.5 (3.1) 6.2 (2.6) 0.4023 
 Platelets (x 109/L) 358 (171) 416 (138) 0.0075 
 Alanine transferase (ALT, U/L) 18 (9) 19 (9) 0.5478 
 Creatinine (mg/dL) 0.28 (0.09) 0.28 (0.07) 0.6068 
A total of 208 children were randomized to either hydroxyurea (N=104) or placebo (N=104).  
One participant was later deemed ineligible, and those data were removed from the dataset.  
Values are shown as the Mean (SD) or the number of study participants with the measure/total 
tested for that measure (% affected). ^Fisher exact test due to the low frequency. 
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Table 3.  Adverse events in the NOHARM study population. 
Hydroxyurea 
(N=104) 
Placebo 
(N=103) 
p-value
Events Participants Events Participants 
Serious Adverse Events 6 6 6 6 
 Bacteremia/Sepsis 2 2 2 2 1.0^ 
 Acute Chest Syndrome/Pneumonia 1 1 2 2 0.62^ 
 Vaso-Occlusive Crisis 0 0 1 1 0.50^ 
 Acute Splenic Sequestration 2 2 0 0 0.50^ 
 Anemia 0 0 1 1 0.50^ 
 Sudden Death 1 1 0 0 1.0^ 
SCA-Related Events (Composite) 
Vaso-occlusive pain crisis, dactylitis, 
acute chest syndrome, splenic 
sequestration or blood transfusion 
47 71 0.001 
Clinical Adverse Events 232 76 308 88 
 Vaso-Occlusive Pain Crisis/Dactylitis 58 38 106 59 0.004 
 Acute Chest Syndrome/Pneumonia 24 21 32 24 0.71 
 Clinical Sepsis 8 6 16 13 0.14 
 Acute Splenic Sequestration  0  0  0  0 - 
 Upper Respiratory Tract Infection 107 54 108 62 0.29 
 Gastrointestinal-related 15 13 15 12 1.0 
 Malaria 5 3 7 7 0.21^ 
 Other infections 8 7 14 14 0.16 
 Others (e.g., injury) 7 7 10 9 0.78 
Clinical Interventions 34 14 53 32 
 Transfusion 14 12 18 17 0.41 
 Hospitalization 20 12 35 28 0.007 
Laboratory Adverse Events 57 31 78 46 
 Anemia 40 25 65 42 0.015 
 Reticulocytopenia 3 3 6 5 0.50^ 
 Neutropenia 2 2 0 0 0.50^ 
 Thrombocytopenia 12 11 4 4 0.11 
 Elevated AST/ALT 0 0 2 1 0.50^ 
 Elevated Bilirubin 0 0 1 1 0.50^ 
Dose-Limiting Toxicities 21 15 17 13 
 Anemia 6 4 8 8 0.36 
 Reticulocytopenia 1 1 5 5 0.12^ 
 Neutropenia 2 2 0 0 0.50^ 
 Thrombocytopenia 12 11 4 4 0.11 
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All serious adverse events (SAE), adverse events (AE), and laboratory adverse events (Lab AE) 
were compared between treatment arms.  Proportions of affected participants were compared 
by Chi-squared tests with Yates correction. ^Fisher exact test instead of Chi-square, due to the 
low expected frequency.  Full definitions of adverse events are provided in Table 1. 
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Month 12 Change from baseline 
Laboratory Measures Hydroxyurea Placebo p-value Hydroxyurea Placebo p-value
Hemoglobin (g/dL) 8.7 (1.3) 7.4 (1.0) <0.001 1.2 (1.2) -0.1 (0.9) <0.001 
Mean corpuscular volume (MCV, fL) 88 (9) 81 (8) <0.001 9 (7) 1 (5) <0.001 
Fetal hemoglobin [(HbF)/(HbF + HbS), %] 22.9 (8.6) 10.4 (4.8) <0.001 8.5 (6.7) -3.1 (3.3) <0.001 
 Enrollment age below median 24.1 (8.5) 12.1 (4.8) <0.001 7.9 (7.4) -4.1 (3.5) <0.001 
 Enrollment age above median 21.4 (8.7) 8.8 (4.2) <0.001 9.3 (5.6) -2.2 (2.8) <0.001 
Absolute reticulocyte count (ARC, x 109/L) 247 (107) 391 (122) <0.001 -144 (119) 11 (119) <0.001 
White blood cell count (WBC, x 109/L) 13.7 (5.1) 18.0 (5.1) <0.001 -5.4 (5.8) -0.7 (5.1) <0.001 
Absolute neutrophil count (ANC, x 109/L) 5.2 (2.5) 6.6 (2.6) <0.001 -1.3 (3.0) 0.4 (3.0) <0.001 
Platelets (x 109/L) 371 (166) 446 (143) <0.001 12 (184) 28 (152) 0.50 
Alanine transferase (ALT, U/L) 19 (8) 18 (8) 0.59 0.8 (11) -0.9 (10) 0.28 
Creatinine (mg/dL) 0.32 (0.11) 0.31 (0.08) 0.64 0.04 (0.13) 0.04 (0.10) 0.92 
Table 4.  Selected laboratory characteristics of the NOHARM randomized population.  Results are shown only for participants who 
had data for the measure both at baseline and at 12 months, as mean (SD) or the percentage of participants affected.  The median 
age at enrollment was 2.2 years.  Treatment group differences at month 12 and changes from baseline were tested by Welch’s t-
tests.
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FIGURE LEGENDS 
Figure 1.  CONSORT diagram for the NOHARM trial. 
Figure 2.  Incidence of malaria events in the NOHARM trial, with no statistical difference 
observed between the blinded treatment arms (p=0.19).  Comparisons of the hydroxyurea to 
placebo group were calculated using Gray’s test for competing events, treating death as a 
competing event.  Solid line = hydroxyurea, dashed line = placebo.  The smaller inset diagram is 
identical to the larger graph, but has a different scale. 
Figure 3.  Cumulative incidence of sickle-related adverse events over 12 months, by blinded 
treatment arm. Key is (A) painful vaso-occlusive crisis, p = 0.004; (B) hospitalization, p = 0.002; 
(C) transfusion, p = 0.27; and (D) pneumonia/acute chest syndrome, p = 0.51.
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Figure 2 
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